Thyroid-sTimulaTing hormone (TSH) -producing pituitary adenomas (TSHoma) are rare, accounting for 0.5-1.1% of all pituitary adenomas [1,2]. The diagnosis of these adenomas can be delayed and most TSH-producing adenomas are macroadenomas [1]. Herein, we report a patient with chronic heart and renal failure who was diagnosed with TSH-producing adenoma and underwent treatment with octreotide and thiamazole to control the level of TSH and thyroid hormone secretion after pituitary trans-sphenoidal surgery.A case of TSH-producing adenoma treated with octreotide in combination with thiamazole for the control of TSH and thyroid hormones after trans-sphenoidal neurosurgery Sayaka Fukushima 1) , Masaki Takahashi 2) , Chihiro Yoneda 1) , Hiroyuki Matsuura 1) , Takenori Haruki 1) , Jun Ogino 1) , Minako Koike 2) , Osami Kubo 4) , Takakazu Kawamata 3) and Naotake Hashimoto 1) abstract. While TSH-producing adenoma (TSHoma) is rare, the diagnosis is often delayed because the clinical features are heterogeneous. The patient was a 69-year-old woman who had been referred to the Yachiyo Medical Center in August 2008, because of dyspnea, loss of appetite, weight loss of 10 kg, and diarrhea that lasted 4 years. We diagnosed this patient with pituitary TSH-producing macroadenoma. Thyroid hormone concentration was increasing although the serum TSH level was within a normal range after trans-sphenoidal surgery. We considered that because of enlargement of the thyroid gland due to long-term stimulation by TSH, a low concentration of TSH could stimulate the thyroid gland to produce excess T3 or T4. The somatostatin analogue, octreotide was used to control the TSHoma and serum TSH concentration but not thyroid hormone. The octreotide in combination with thiamazole treatment for 14 months controlled thyroid hormone concentration and decreased the thyroid mass, and ultimately, the thiamazole could be stopped. To date, the use of combination therapy of octreotide with thiamazole in patients with remaining TSH-producing adenoma without Basedow's disease is rare, and we suggest that this treatment is one of the therapeutic means to treat recurrence of TSH-producing adenoma after surgery with progressive complications or large thyroid gland.